Nivolumab vs investigatorʼs choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression - Ferris, R L; Blumenschein, G, Jr; Fayette, J (Oral Oncol, 2018)
et al.